• Biophytis filed registration in Hong Kong for a joint venture with Asian partners including China’s Ronghui Renhe Life Technology.
• The venture, Biophytis Biopharmaceutical Holding LTD, targets development and commercialization of BIO101 for sarcopenia in Asian markets.
• Asian partners plan to pay an initial USD 3 million toward a USD 20 million commitment to fund clinical and regulatory work through approval.
• Biophytis will contribute patents plus a BIO101 commercialization license covering China, Japan, South Korea.
• Closing expected in coming weeks; phase 3 trial preparation in Asia set as the first operational priority.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Biophytis SA published the original content used to generate this news brief on June 02, 2026, and is solely responsible for the information contained therein.